- 34% overall response rate in 79 evaluable patients with measurable disease
- 9.1 months median duration of response
- Tumor reduction in 70% of patients
- Zeno observed to be very well-tolerated
- Potential new standard of care for patients with NRG1+ cancer
- Investor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center (MSKCC) at the 2022 ASCO Annual meeting.
“We have made significant progress with enrollment in the eNRGy trial over the past year,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “And Zeno continues to demonstrate consistent efficacy in patients with multiple types of NRG1+ cancer. We believe Zeno has the potential to be both first in class and best in class as a tumor agnostic treatment for patients with NRG1+ cancer.”
Dr. Schram added, “Zeno has led to durable responses in previously treated NRG1 fusion-positive cancer, with a median duration of response greater than 9 months and more than 25% of those responding continuing at 12 months. Additionally, Zeno has an extremely well tolerated safety profile. There are currently no approved therapies targeting NRG1 fusion-positive cancer and Zeno offers an important, potential new standard of care.”
The reported data are from the phase 1/2 eNRGy trial and EAP which are assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
Date: Sunday, June 5, 6:00 p.m. CT
Webcast link: available on our website
Dial-in: Toll-free: 18772601463/ International: 17066435907
Conference ID: 7194538
https://www.marketscreener.com/quote/stock/MERUS-N-V-27548017/news/Merus-Presents-Clinical-Data-on-Zenocutuzumab-Zeno-in-NRG1-fusion-NRG1-Cancer-at-the-2022-Ameri-40646494/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.